US study finds 700,000 adverse effects cases

30 October 2006

A study published in the Journal of the American Medical Association has found that an estimated 701,547 people each year visit Emergency Departments because of adverse reactions to drugs or supplements.

The most common causes of adverse reactions were accidental overdoses or allergic reactions, the former of which typically involved either: insulins for diabetes; opiate-containing painkillers; or bloodthinners. Drugs most commonly involved in allergic reactions were antibiotics containing amoxicillin and anti-histamines, as well as over-the-counter cold remedies. Emergency patients in these cases were twice as likely to be over 65 than younger and seven times more likely to require a hospital stay.

The data were compiled from 63 representative hospitals across the USA that reported 21,298 adverse drug reactions in emergency patients.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight